8-K: Supernus Sets Date for Q4 and Full Year 2025 Earnings Call

Supernus Pharmaceuticals, Inc. announced it will report its fourth quarter and full year 2025 financial results on February 24, 2026, after market close.

Summary

• Supernus Pharmaceuticals, Inc. will announce its fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026.
• A conference call and webcast will be hosted by Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, on Tuesday, February 24, 2026, at 4:30 p.m. ET.
• The call will include management's prepared remarks, a discussion of business results, and a question-and-answer session.
• A live webcast will be available in the Events & Presentations section of the Company's Investor Relations website at www.supernus.com/investors.
• Participants can pre-register for the call to receive a personalized dial-in number and conference code.
• A replay of the webcast will be available on the Company's Investor Relations website for 60 days following the live call.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, procedural announcement. It provides no new financial data or operational updates beyond the scheduling of the earnings release, thus having no immediate positive or negative sentiment impact.

Risks

• Ability to sustain and increase profitability.
• Ability to raise sufficient capital to fully implement corporate strategy.
• Implementation of corporate strategy.
• Future financial performance and projected expenditures.
• Ability to increase the number of prescriptions written for products.
• Ability to increase net revenue from products.
• Ability to commercialize products.
• Ability to enter into future collaborations with pharmaceutical companies and academic institutions or obtain funding from government agencies.
• Product research and development activities, including timing and progress of clinical trials and projected expenditures.
• Ability to receive, and timing of any receipt of, regulatory approvals for product candidates.
• Ability to protect intellectual property and operate without infringing on others' intellectual property rights.
• Expectations regarding federal, state, and foreign regulatory requirements.
• Therapeutic benefits, effectiveness, and safety of product candidates.
• Accuracy of estimates of market size and characteristics for product candidates.
• Ability to increase manufacturing capabilities for products and product candidates.
• Projected markets and growth in markets.
• Product formulations, patient needs, and potential funding sources.
• Staffing needs.
• Changes to laws and regulations applicable to the industry.
• Impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, and tariffs.

Future Outlook

The filing primarily announces the schedule for the upcoming fourth quarter and full year 2025 financial results and conference call. It reiterates the company's focus on developing and commercializing products for central nervous system (CNS) diseases and mentions a broad range of novel product candidates under development. Forward-looking statements highlight various risks and uncertainties that could impact future results, including profitability, capital raising, strategic implementation, and regulatory approvals.

Management Comments

• Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the fourth quarter and full year 2025 financial and business results.

Industry Context

StockSavvy.ai notes that this announcement is a standard procedural step for a publicly traded biopharmaceutical company, signaling transparency and adherence to reporting schedules. The focus on CNS diseases aligns with a growing area of pharmaceutical research and development, driven by increasing prevalence of neurological and psychiatric disorders globally. Competitors in this space include major pharmaceutical companies with established neuroscience portfolios and smaller biotech firms developing specialized treatments.

Stakeholder Impact

• Shareholders and potential investors will receive updated financial and business performance information for Q4 and full year 2025, which could influence investment decisions.
• Analysts will use the upcoming earnings call to update their models and recommendations based on the reported results and management's commentary.

Next Steps

• Supernus Pharmaceuticals, Inc. will report fourth quarter and full year 2025 financial and business results after market close on February 24, 2026.
• The company will host a conference call and webcast on February 24, 2026, at 4:30 p.m. ET to discuss the results.
• A replay of the webcast will be available on the company's Investor Relations website for 60 days following the live call.

Key Dates

Keywords

Supernus Pharmaceuticals, SUPN, Earnings Call, Financial Results, Q4 2025, Full Year 2025, Biopharmaceutical, CNS Diseases, Investor Relations, Nasdaq